IP Verse

Amgen patent opposition analysis

CompanyCompetitive AnalysisCompany Patent Opposition Analysis

Latest oppositions filed by Amgen

Explore patent oppositions filed by Amgen against competitors, revealing strategic technology disputes and market positioning. Monitor opposition details, timelines, and disputed innovations to understand competitive dynamics and IP enforcement strategy.

Last updated on: Aug 21, 2025
Patent NumberTitleApplicantOpposition Date

Get instant updates on new opposition filings by the company

EP4252857
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)REGENERON PHARMACEUTICALSJun 23, 2025
EP3167888
Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of ComplementALEXION PHARMACEUTICALSOct 28, 2024
EP3384049
Methods Of Associating Genetic Variants With A Clinical Outcome In Patients Suffering From Age-Related Macular Degeneration Treated With Anti-VegfREGENERON PHARMACEUTICALSApr 22, 2024
EP3536712
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)REGENERON PHARMACEUTICALSFeb 29, 2024
EP3345607
Methods Of Altering Bone Growth By Administration Of Sost Or Wise Antagonist Or AgonistOSSIFI MABJul 26, 2023
EP2894165
Methods And Compositions For Treating Complement-Associated DisordersALEXION PHARMACEUTICALSMay 17, 2023
EP3716992
Use Of A Vegf Antagonist To Treat Angiogenic Eye DisordersREGENERON PHARMACEUTICALSMay 10, 2023
EP3230316
Treatment Of Age Related Macular Degeneration With A Small Active Choroidal Neovascularization LesionBAYER HEALTHCAREOct 5, 2022
EP2825558
Combination Therapy For The Treatment Of Ovarian CancerFHOFFMANN LA ROCHEFeb 17, 2020
EP2756004
Methods For Reducing Lipoprotein(A) Levels By Administering An Inhibitor Of Proprotein Convertase Subtilisin Kexin-9 (Pcsk9)REGENERON PHARMACEUTICALSDec 27, 2019

Latest patents of Amgen opposed by its competitors

Explore Amgen's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Aug 21, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP3661562
Oct 2, 2024Method Of Conjugation Of Cys-Mabs1
EP3570885
Sep 18, 2024Method Of Treating Or Ameliorating Metabolic Disorders Using Glp-1 Receptor Agonists Conjugated To Antagonists For Gastric Inhibitory Peptide Receptor (Gipr)3
EP4209499
Aug 7, 2024Charged Depth Filtration Of Antigen-Binding Proteins7
EP3819007
Jul 10, 2024Dosing Regimen For Anti-Bcma Agents2
EP3926051
May 8, 2024Methods For Harvesting Mammalian Cell Cultures1
EP3151882
Apr 10, 2024Controllable Drug Delivery System And Method Of Use2
EP2637670
Mar 13, 2024Prevention Of Adverse Effects Caused By Cd3 Specific Binding Domains2
EP4058148
Mar 13, 2024Dosing Regimen For Anti-Bcma Agents3
EP3152694
Mar 6, 2024Systems And Methods For Remotely Processing Data Collected By A Drug Delivery Device1
EP3615066
Dec 27, 2023Formulations Of Human Anti-Rankl Antibodies, And Methods Of Using The Same1

Top competitors of Amgen

Top competitors of Amgen based on patent oppositions.